Insulet revenue jumps 36 percent as losses narrow
Insulet Corp. (NSDQ:PODD) reported a loss of $12.1 million, or 30 cents per diluted share, on revenue of $25.5 million during the three months ended Sept. 30. That compares with a loss of $16.9 million, or 60 cents per diluted share, on revenue of $18.7 million during the same period last year.
Read more
Theragenics Corp. sales increase 6 percent, but profits weaken
Theragenics Corp. (NYSE:TGX) reported profits of approximately $771,000, or 2 cents per diluted share, on revenue of $20.4 million during the three months ended Sept. 30. That compares with profits of approximately $799,000, or 2 cents per diluted share, on revenue of $19.0 million during the same period last year.
Read more
Accellent losses nearly quadruple
Accellent Holdings Corp. subsidiary Accellent Inc. posted a loss of $3.1 million on sales of $125.0 million during the three months ended Sept. 30. That compares with a net loss of approximately $820,000 on sales of $117.8 million during the same period last year.
Read more
Losses outstrip revenue at NMT Medical
NMT Medical Inc. (NSDQ:NMTI) posted a loss of $3.4 million, or 21 cents per diluted share, on sales of $2.1 million during the three months ended Sept. 30. That compares with a loss of $2.9 million, or 22 cents per diluted share, on sales of $3.0 million during the same period last year.
Read more
Angiotech losses increase as revenue drops
Angiotech Pharmaceuticals Inc. (NSDQ:ANPI) reported a net loss of $18.5 million, or 22 cents per diluted share, on sales of $59.0 million during the three months ended Sept. 30. That compares with a loss of $7.8 million, or 9 cents per diluted share, on sales of $63.2 million during the same period last year.
Read more
Bovie Medical squeaks out a profit
Bovie Medical Corp. (NYSE:BVX) recorded profits of $4,236 on revenue of $6.5 million during the three months ended Sept. 30. That compares with a loss of $37.7 million on sales of $6.4 million during the same period last year.
Read more
Clinical Data losses ease
Clinical Data Inc. (NSDQ:CLDA) recorded a loss of $16.6 million, or 56 cents per diluted share, on sales of $3.4 million during the three months ended Sept. 30. That compares with a loss of $18.7 million, or 79 cents per diluted share, on sales of $3.0 million during the same period last year.
Read more
